(385) 250-0900

Tissue Regeneration Sciences, Inc.

Commercializing tissue regeneration technologies CONTACT US

Tissue Regeneration Sciences, Inc.

Commercializing tissue regeneration technologies CONTACT US

Tissue Regeneration Sciences, Inc is an early stage biotechnology venture founded on the patented tissue regenerative technology of calreticulin. Our mission is to develop and commercialize healing and tissue regenerative technologies to improve patient quality of life.

About Tissue Regeneration Sciences (TRS)

An early stage biotechnology venture founded on the potent novel biotherapeutic, calreticulin, that heals wounds by tissue regeneration.

FIRST INDICATION: Developing the first topical drug treatment for diabetic foot ulcers (DFUs), a serious unmet medical need.

Core Tissue Regeneration Indications


Tissue regeneration of chronic cutaneous wounds including diabetic foot ulcers, pressure ulcers (bed sores), and venous stasis ulcers


Cosmetic soft tissue augmentation for the treatment of fine lines and wrinkles


Ophthalmic ulcers (e.g., corneal abrasions)


Tissue Reconstruction


Cartilage and bone regeneration


Regeneration of new hair follicles


Orphan indication of sickle cell skin ulcerations

Our Team

Leslie I. Gold, PhD


Leslie I Gold, Ph.D., is Associate Professor of Pathology and Medicine at the New York University School of Medicine. Her background is in biochemistry, protein chemistry, and cell biology.  Learn more here.

Eric R. Hermann, MALD


Eric R. Hermann has invested in life sciences startups for over fifteen years, beginning with Curemark, LLC where he serves as a Director. He has supported Dr. Gold’s work since 2010. Learn more here.

Dr. Stephen M. W. Chang, PhD


Stephen Mon Wei Chang, PhD has over 30 years of commercial experience in life sciences, focusing on stem cells, cell and gene therapy, and drug development.
Learn more here.

Key Consultants and Legal Advisors

Dr. Oscar M. Alvarez, PhD, CCT, FAPWCA

Dr. Alvarez obtained a Bachelor of Science degree in Pre-Med and Chemistry from the University of Dayton (1974) and his doctorate in Nutritional Biochemistry from Rutgers University in 1979. Dr. Alvarez has been the recipient of more than 80 research grants and awards, including: a National Institute of Health Training Award to study dermal-epidermal interactions during wound repair, a US Army Medical Research and Development Command Award to study epidermal migration in partial thickness wounds, and a National Institute of Health grant to study Emotional Stress and Wound Healing in Diabetics. Learn more here.

Scientific Advisory Board

Vickie R. Driver, DPM MS FACFAS

Dr. Driver is a Fellow at the American College of Foot and Ankle Surgeons, is board certified in foot surgery by the American Board of Podiatric Surgery, and is a Fellow, Royal College of Physicians and Surgeons – Glasgow. She is the Director of Translational Medicine Wound Healing at Novartis Institute for BioMedical Research. Dr. Driver is dedicated to furthering both the understanding of the natural history of disease and the discovery of new therapies and diagnostics to advance the treatment of patients who suffer with wounds and are at risk of limb loss. She is an outspoken ambassador for progressive change in this field. Learn more here.

Luciano V. Del Priore, MD, PhD

Luciano V. Del Priore, MD, PhD specializes in the surgical and medical treatment of retinal disease, including age-related macular degeneration, retinal detachment, diabetic retinopathy, macular holes, epiretinal membranes and ocular trauma. Dr. Del Priore is the Robert R. Young Professor and Chair of the Department of Ophthalmology & Visual Science at Yale School of Medicine. He is Chief of Ophthalmology at Yale New Haven Hospital. Learn more here.


Marek Michalak, PhD

Marek Michalak, PhD, is a Distinguished Professor at the University of Alberta where he served for many years as Chair of the Department of Biochemistry and as a Vice-Dean (Research), Faculty of Medicine & Dentistry. He has received numerous academic distinctions including the University Cup which is among the highest honors that the University of Alberta confers on faculty. Learn more here.


Jessica B. Swartz, PhD

Jessica Swartz, PhD, is a biopharmaceutical professional with 8+ years of expertise in strategy, commercial development & business development. She currently leads the Strategy & Execution team for Pfizer’s Vaccines and Hospital business units. Prior roles include VP of BD & Operations for Regenovation; strategy and competitive intelligence roles for Pfizer’s Essential Health business and Neuroscience research unit; and Engagement Manager at IMS Consulting Group specializing in product and portfolio strategy.  Learn more here.


Pre-Clinical Trials

TRS is undertaking preclinical studies to enable filing INDs for initial indications of cutaneous tissue regeneration for chronic and acute wounds, healing of corneal wounds, soft tissue augmentation, and hair follicle neogenesis and to further mechanisms of action of calreticulin in the various indications.

Intellectual Property

All clinical applications of calreticulin described herein are protected by US and European issued and pending patents.



Pandya UM and Gold LI. The novel biotherapeutic calreticulin (CRT) corrects multiple defects of non-healing diabetic wounds. J Dermatol and Clin Res. 2016, 4(5) 1083-1095 (Cover Article).


Greives MR, Samra F, Pavlides SC, Blechman KM, Naylor SM, Woodrell CD, Cadacio C, Levine JP, Bancroft TA, Michalak M, Warren SM, Gold LI. Exogenous calreticulin improves diabetic wound healing. Wound Repair Regen. 2012 Sep-Oct;20(5):715-30. PubMed PMID: 22985041.


Nanney LB, Woodrell CD, Greives MR, Cardwell NL, Pollins AC, Bancroft TA, Chesser A, Michalak M, Rahman M, Siebert JW, Gold LI. Calreticulin enhances porcine wound repair by diverse biological effects. Am J Pathol. 2008 Sep;173(3):610-30. PubMed PMID: 18753412; PubMed Central PMCID: PMC2527067.

Want to Learn More?